Free Trial
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

Galmed Pharmaceuticals logo
$2.75 -0.21 (-7.09%)
(As of 02:20 PM ET)

About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)

Key Stats

Today's Range
$2.75
$2.94
50-Day Range
$2.88
$15.10
52-Week Range
$2.73
$23.80
Volume
41,791 shs
Average Volume
759,034 shs
Market Capitalization
$1.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
24th Percentile Overall Score

GLMD MarketRank™: 

Galmed Pharmaceuticals scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Galmed Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galmed Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galmed Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Galmed Pharmaceuticals has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Galmed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.08% of the float of Galmed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Galmed Pharmaceuticals has recently increased by 73.86%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Galmed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Galmed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.08% of the float of Galmed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Galmed Pharmaceuticals has recently increased by 73.86%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Galmed Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
  • Search Interest

    2 people have searched for GLMD on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Galmed Pharmaceuticals' insider trading history.
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Stock News Headlines

Galmed Pharmaceuticals Amends Equity Purchase Agreement
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
See More Headlines

GLMD Stock Analysis - Frequently Asked Questions

Galmed Pharmaceuticals' stock was trading at $5.46 at the beginning of the year. Since then, GLMD shares have decreased by 47.1% and is now trading at $2.89.
View the best growth stocks for 2024 here
.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its earnings results on Wednesday, August, 28th. The biopharmaceutical company reported $2.16 EPS for the quarter.

Galmed Pharmaceuticals shares reverse split on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol-Myers Squibb (BMY), Plug Power (PLUG), Applied Genetic Technologies (AGTC) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/28/2024
Today
11/21/2024
Next Earnings (Estimated)
11/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLMD
Employees
20
Year Founded
N/A

Profitability

Net Income
$-6,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$28.64 per share

Miscellaneous

Free Float
516,000
Market Cap
$1.89 million
Optionable
Not Optionable
Beta
0.80

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:GLMD) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners